iASPP is important for bladder cancer cell proliferation

Oncology Research

Volumn 19, Issue 3-4, 2011, Pages 125-130

  Liu, Tao ^a   Li, Lin ^b   Yang, WenFeng ^c   Jia, Hui ^a   Xu, MingKai ^d   Bi, JianBin ^a   Li, ZeLiang ^a   Liu, XianKui ^a   Li, ZhenHua ^a   Jing, HongWei ^a   Kong, ChuiZe ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Handan First Hospital   (China)

^d INSTITUTE OF APPLIED ECOLOGY   (China)

Author keywords

Bladder cancer; iASPP; Proliferation; RNA interference

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROXURIDINE; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS STIMULATORY PROTEIN PHOSPHATASE; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER CELL; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LENTIVIRINAE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79952390201     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12935427587768     Document Type: Article

References (27)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108; 2005.
2. Catto, J. W. F.; Azzouzi, A. R.; Rehman, I.; Feeley, K. M.; Cross, S. S.; Amira, N.; Fromont, G.; Sibony, M.; Cussenot, O.; Meuth, M.; Hamdy, F. C. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 23:2903-2910; 2005.
3. Friedrich, M. G.; Weisenberger, D. J.; Cheng, J. C.; Chandrasoma, S.; Siegmund, K. D.; Gonzalgo, M. I.; Huland, H.; Yoo, C.; Tsai, Y. C.; Nichols, P. W.; Bochner, B. H.; Jones, P. A.; Liang, G. N. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10:7457-7465; 2004.
4. Engel, L. S.; Taioli, E.; Pfeiffer, R.; Garcia-Closas, M.; Marcus, P. M.; Lan, Q.; Boffetta, P.; Vineis, P.; Autrup, H.; Bell, D. A.; Branch, R. A.; Brockmöller, J.; Daly, A. K.; Heckbert, S. R.; Kalina, I.; Kang, D.; Katoh, T.; Lafuente, A.; Lin, H. J.; Romkes, M.; Taylor, J. A.; Roth man, N. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: A HuGE review. Am. J. Epidemiol. 156:95-109; 2002.
5. Marcus, P. M.; Vineis, P.; Rothman, N. NAT2 slow acetylation and bladder cancer risk: A meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 10:115-122; 2000.
6. Ardavanis, A.; Tryfonopoulos, D.; Alexopoulos, A.; Kandylis, C.; Lainakis, G.; Rigatos, G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study. Br. J. Cancer 92:645-650; 2005.
7. Sternberg, C. N. The treatment of advanced bladder cancer. Ann. Oncol. 6:113-126; 1995.
8. Samuels-Lev, Y.; O'Connor, D. J.; Bergamaschi, D.; Trigiante, G.; Hsieh, J.; Zhong, S.; Campargue, I.; Naumovski, L.; Crook, T.; Lu, X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell. 8:781-794; 2001.
9. Ahn, J.; Byeon, I. J.; Byeon, C. H.; Gronenborn, A. M. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J. Biol. Chem. 284: 13812-13822; 2009.
10. Sullivan, A.; Lu, X. ASPP: A new family of oncogenes and tumour suppressor genes. Br. J. Cancer 96:196-200; 2007.
11. Liu, Z. J.; Lu, X.; Zhang, Y.; Zhong, S.; Gu, S.; Zhang, X.; Yang, X.; Xin, H. Downregulated mRNA expression of ASPP and the hypermethylation of the 5′-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett. 579:1587-1590; 2005.
12. Robinson, R. A.; Lu, X.; Jones, E. Y.; Siebold, C. Bio- chemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure 16: 259-268; 2008.
13. Patel, S.; George, R.; Autore, F.; Fraternali, F.; Ladbury, J. E.; Nikolova, P. V. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res. 36:5139-5151; 2008.
14. Tidow, H.; Andreeva, A.; Rutherford, T. J.; Fersht, A. R. Solution structure of ASPP2 N-terminal domain (N- ASPP2) reveals a ubiquitin-like fold. J. Mol. Biol. 371: 948-958; 2007.
15. Bergamaschi, D.; Samuels, Y.; O'Neil, N. J.; Trigiante, G.; Crook, T.; Hsieh, J. K.; O'Connor, D. J.; Zhong, S.; Campargue, I.; Tomlinson, M. L.; Kuwabara, P. E.; Lu, X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33:162-167; 2003.
16. Bell, H. S.; Ryan, K. M. iASPP inhibition: Increased options in targeting the p53 family for cancer therapy. Cancer Res. 68:4959-4962; 2008.
17. Liu, Z. J.; Cai, Y.; Hou, L.; Gao, X.; Xin, H. M.; Lu, X.; Zhong, S.; Gu, S. Z.; Chen, J. Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest. 26:878-882; 2008.
18. Mantovani, F.; Tocco, F.; Girardini, J.; Smith, P.; Gasco, M.; Lu, X.; Crook, T.; Sal, G. D. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat. Struct. Mol. Biol. 14: 912-920; 2007.
19. Zhang, X.; Wang, M.; Zhou, C.; Chen, S.; Wang, J. The expression of iASPP in acute leukemias. Leuk. Res. 179-183; 2005.
20. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408; 2001.
21. Marceau, N. Cell lineages and differentiation programs in epidermal, urothelial and hepatic tissues and their neoplasms. Lab. Invest. 63:4-20; 1990.
22. Limas, C.; Bair, R.; Bernhart, P.; Reddy, P. Proliferative activity of normal and neoplastic urothelium and its relation to epidermal growth factor and transferrin receptors. J. Clin. Pathol. 46:810-816; 1993.
23. Stewart, F. A. Mechanism of bladder damage and repair after treatment with radiation and cytostatic drugs. Br. J. Cancer Suppl. 7:280-291; 1986.
24. Moonen, L.; Ong, F.; Gallee, M.; Verheij, M.; Horenblas, S.; Hart, A. A.; Bartelink, H. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys. 49:1305-1310; 2001.
25. Cote, R. J.; Datar, R. H. Therapeutic approaches to bladder cancer: Identifying targets and mechanisms. Crit. Rev. Oncol. Hematol. 46(Suppl.):S67-83; 2003.
26. Dibbelt, L. Does trisialo-transferrin provide valuable information for the laboratory diagnosis of chronically increased alcohol consumption by determination of carbohydrate-deficient transferring? Clin. Chem. 46:1203-1205; 2000.
27. Laska, M. J.; Strandbygard, D.; Kjeldgaard, A.; Mains, M.; Corydon, T. J.; Memon, A. A.; Sørensen, B. S.; Vogel, U.; Jensen, U. B.; Nexø, B. A. Expression of the RAI gene is conducive to apoptosis: Studies of induction and interference. Exp. Cell Res. 313:2611-2621; 2007.